The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis
出版年份 2017 全文链接
标题
The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis
作者
关键词
-
出版物
POSTGRADUATE MEDICINE
Volume 130, Issue 1, Pages 129-136
出版商
Informa UK Limited
发表日期
2017-11-15
DOI
10.1080/00325481.2018.1401421
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins
- (2017) Amanda L. Brown et al. JOURNAL OF LIPID RESEARCH
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy
- (2017) Theodosios D. Filippatos et al. Journal of Thoracic Disease
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
- (2016) Hidenori Arai et al. ATHEROSCLEROSIS
- Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia
- (2016) Claudio Borghi et al. Expert Opinion on Drug Metabolism & Toxicology
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
- (2015) Sam J. L. van der Tuin et al. JOURNAL OF LIPID RESEARCH
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
- (2015) John J P Kastelein et al. LANCET
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
- (2013) Tamio Teramoto et al. ATHEROSCLEROSIS
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
- (2011) Philip J. Barter et al. CIRCULATION
- Forecasting the Future of Cardiovascular Disease in the United States
- (2011) Paul A. Heidenreich et al. CIRCULATION
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
- (2010) Eric J. Niesor et al. JOURNAL OF LIPID RESEARCH
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans
- (2009) S. Kumar et al. DRUG METABOLISM AND DISPOSITION
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
- (2008) Daniel Bloomfield et al. AMERICAN HEART JOURNAL
- Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
- (2008) R Krishna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
- (2008) Alexander Thompson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started